# Identify The Need For Change Using Audit

Shirley Murray N. Ireland Coordinator of Haemovigilance Services

# Objectives

- Identifying the need
- Developing a formula that works
- How one thing leads to another
- Impact of findings

# N.I. Red Cell Guidelines (2001)


- If Haemoglobin is > 10g/dl don't transfuse
- If Haemoglobin is <7g /dl transfuse
- If Haemoglobin is 7-10g /dl transfuse if symptomatic

# N.I. Audit

- Agreement of NITC
- Application for funding to GAIN (*Guidelines and Audit Improvement Network*)
- Development of lead audit group
- External peer reviewer
- Audit standards
- Proforma and pilot
- Training of auditors

## Indication for red cell transfusion


Age<65yrs	Hb < 7 g/dl
Age > 65yrs	Hb < 8g/dl
Cardiac/cerebrovascular symptoms	Hb <9 g/dl
Significant haemorrhage	>500ml/hr
Bone marrow failure symptoms	Hb<10g/dl
Patient on chemo/Radiotherapy	Hb<10g/dl
Symptomatic of anaemia	Hb <10g/dL




### Red Cell Audit 2006


19% of patients had an inappropriate transfusion 29% of patients were overtransfused

85% of transfused patients were admitted to hospital with anaemia Haemoglobin on Admission to Hospital (2006 Audit)






### Inappropriate Transfusion By Grade Of Doctor




# Inappropriateness of Transfusion by Patient Criteria



### NIRTC Audit 2006

- Dissemination of results in hardcopy and PDF
- Multiprofessional conference



### Northern Ireland Regional Transfusion Committee

#### **TRANSFUSION THRESHOLDS**

Is your patient a 7, 8, 9 or 10?

- In healthy stable adults under 65 years old without cardiac or cerebrovascular disease. Consider transfusion only when haemoglobin is below 7g/dl
- In older healthy adults without cardiac or cerebrovascular disease who are above 65 transfusion should only be considered when the haemoglobin is below 8g/dl
- In patients with known cardiac or cerebrovascular disease, consideration should be given if the haemoglobin is below 9g/dl and is probably indicated below 8g/dl
- In sustained heavy bleeding (>500ml/hour) without likelihood of stopping, it may be necessary to transfuse when the haemoglobin is below 10g/dl
- "Tiredness" is not an adequate symptom alone to tranfuse
- In truly symptomatic patients with either dyspnoea, angina, hypertension, tachycardia, orthostatic hypotension and syncope that is due to anaemia transfusion is appropriate for haemoglobin levels below 10g/dl

The NIRTC Regional Transfusion Audit of 1220 cases showed an inappropriate transfusion rate of 19% of patients and an overtransfusion rate of 29%

 Overtransfusion (>2g/dl above the threshold level) is common and a single unit in small patients may raise the haemoglobin by 2.5g/dl or more

> Advice compatible with NIRTC recommendations 2006, CMO letter 2006 & CREST guidelines 2007

### Northern Ireland Regional Transfusion Committee

#### IS BLOOD TRANSFUSION NECESSARY?

- There is no 'universal' trigger for blood transfusion
- Transfusion given at any haemoglobin level can cause morbidity and mortality

Unnecessary transfusion increases the risk

 Transfusion should not be used to treat iron deficiency anaemia - the treatment of choice here is oral iron or if this is not tolerated or adequate - intravenous iron

#### CONSENT FOR BLOOD TRANSFUSION

When a decision to transfuse has been taken - it is important to explain the following so that the patient can make an informed choice about receiving the transfusion.

- Explain why the transfusion is being given and the perceived benefit
- Explain that there is no suitable alternative treatment
- Explain that receiving a transfusion unfortunately means the patient can never be a blood donor (concern over the possible spread of CJD)
- Discuss minor common problems with transfusion (3-5%) - high temperature, rash, shivering
- Discuss major but less common problems, e.g. incompatible transfusion and major reactions (approximately 1 in 10,000 per unit transfused)

# New N.I. Standards




# 2006 Audit


### 85% of transfused patients were admitted to hospital with anaemia


- Audit not designed to examine whether anaemia was diagnosed, investigated or treated correctly prior to transfusion.
- An application to investigate pre hospital admission anaemia was made to GAIN
- Same approach with modified lead audit group

### **Key Findings**


### Could transfusion have been avoided?










Avoidable transfusion by admitting speciality



### **Overtransfusion**








16%

### **Inappropriate Transfusion**








### **Dissemination of Results**

Audit results circulated

# •Multiprofessional conference



NI Transfusion Committee June 2012

#### **4 STEPS IN THE INVESTIGATION AND MANAGEMENT OF THE ADULT PATIENT WITH ANAEMIA**

		5	TEP	1			
Perform	FBP	test	for H	Ιb,	MCV	and	MC

If patient anaemic as per \* WHO Classification of anaemia follow steps below

STEP 2 MCV or MCH low: perform iron studies (including serum ferritin)

MCV & MCH normal range: perform iron studies & renal function tests, serum folate & vitamin B12 levels

MCV or MCH high: perform LFTs, thyroid function, serum folate and vitamin B12 levels

#### STEP 3

1. Start appropriate corrective therapy for an aemia without delay (e.g. or al iron therapy)

AND

 Investigate cause of anaemia unless already known or further investigation is not in the patient's best interests (e.g. palliative care)

STEP 4 1. Monitor response to corrective therapy for an aemia, including rise in Hb

AND

2. Treat the cause of an aemia (e.g. surgery for carcinoma of bowel)

#### \* WHO Classification of anaemia

Haemoglobin: <13 g/dl in adult male <12 g/dl in adult female <11 g/dl in pregnancy

#### Abbreviations used:

FBP: full blood picture

Hb: Haemoglobin

MCV: Mean corpuscular volume

MCH: Mean corpuscular haemoglobin

WCC: white blood cell count

CRP: C-reactive protein

TIBC: total iron binding capacity

TSAT: transferrin saturation

LFTs: liver function tests


ESA: erythrocyte stimulating agent or recombinant erythropoietin

eGFR: estimated glomerulofiltration rate


CKD: chronic kidney disease


Sickle cell disease – perform Sickledextest if positive family history or patient's genetic origin is West Africa


#### 4 STEPS IN THE INVESTIGATION AND MANAGEMENT OF THE ADULT PATIENT WITH ANAEMIA MACROCYTIC ANAEMIA



#### 4 STEPS IN THE INVESTIGATION AND MANAGEMENT OF THE ADULT PATIENT WITH ANAEMIA MICROCYTIC ANAEMIA








#### MANAGEMENT OF THE ANAEMIC ADULT PATIENT PRIOR TO SCHEDULED MAJOR SURGERY

(Also applicable to other invasive procedures with potential for blood loss) WHO definition of anaemia<sup>2</sup>: adult male < 13g/dl; adult female < 12g/dl; pregnant female < 11g/dl



TIBC - Total Iron Binding Capacity TSAT - transferrin saturation in % NSAIDs - Non Steroidal Anti-Inflammatory Drugs, e.g. Diciotanac, Ibuprofen LMWH - Low Molecular Weight Heparin, e.g. Epoxaparin, Epidaparinux

- Musailam et al. Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. www.thelancet.com October 2011.
- 2. World Health Organisation. Worldwide Prevalence of Anaemia 1993-2005. WHO, 2008
- Goodnough et al. Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines BJA 2011; 106: 13-22
- 4. Skinner CM and Eanglasani. Preoperative use of herbal medicines: a patient survey J BJA 2002; 89: 792-5.

# **Advantages of Funded Audits**

- Ownership of result
- Ability to carryout large scale audits
- Option to carryout audit within or outside of NHS hours
- Multi-professional auditors
- Support from commissioners and N.I. Blood Safety Advisory Committee more readily available
- Admin and conference support

# Audit Funding to Date


Appropriate use of red cells Pre hospital admission anaemia Appropriate use of IgG Appropriate use of platelets Appropriate use of FFP Appropriate use of Anti D

£29,918 £25,000 £26,400 £18,060 £5,000 £28,000

£142,378

### **Red Cell issues**

6 Monthly Moving Average



# Estimated Product and Component Cumulative Savings

• All funded audits plus unfunded 5% Albumin audit. Based on pre-audit trends

### £10,000,000 over 7 years